390
Views
4
CrossRef citations to date
0
Altmetric
Patent Evaluations

Evaluation of WO2013125543, WO2013146963 and EP2634185: the first Tyk2 inhibitors from Takeda and Sareum

, MBA PhD
Pages 361-368 | Published online: 03 Jan 2014
 

Abstract

Three patent applications, from two different companies, claim structurally novel Tyk2 inhibitors and their uses for the treatment of autoimmune diseases. In EP-2634185 Sareum claims 5-anilino-2-(2-halophenyl)-oxazole-4-carboxamide derivatives which are shown to be nanomolar potency Tyk2 inhibitors with 10 – 100-fold selectivity over JAK1, JAK2 and JAK3. Takeda's WO-2013125543 and WO-2013146963 claim two distinct structural classes of Tyk2 inhibitors. The first application claims inhibitors based on an unusual 1,5-dihydro-4H-pyrazolo[4,3-c]pyridine-4-one scaffold and the second claims 1-(2-arylaminopyrimidin-4-yl)-pyrrolidin-2-one derivatives. One example of the latter was shown to be orally active in an IL-23-induced inflammation model.

Declaration of interest

The author received an honorarium from Informa in preparation of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.